Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab with or without other agents in high‑risk BCG‑unresponsive NMIBC
2014-004026-17Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in non-muscle-invasive bladder cancer (NMIBC) and bladder cancer (3 cohorts), sponsored by Merck & Co. Primary endpoint: Complete response rate of high-risk NMIBC (Cohorts A and C). Started Nov 2015; status: active.
02
Drugs
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)bladder cancer
Beyond the preview
Go deeper on 2014-004026-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004026-17.